Introduction
============

Lung cancer remains the leading cause of cancer-associated mortality, annually resulting in \>1,000,000 mortalities globally in 2012 ([@b1-ol-0-0-10146]). Additionally, \~1,200,000 new cases are diagnosed every year and prognoses of lung cancer are poor, as estimated worldwide in 2012 ([@b2-ol-0-0-10146]). Lung adenocarcinoma is the predominant histological subtype of non-small lung cancer ([@b3-ol-0-0-10146]). The mean 5-year survival rate of lung adenocarcinoma is \<15% in the urban areas of China as estimated in 2015, primarily due to the late-stage detection and a paucity of late-stage treatments ([@b4-ol-0-0-10146]). The availability of effective anticancer drugs is considered to be the key for improvement in the treatment of lung adenocarcinoma.

7, 8-Diacetoxy-4-methylcoumarin (DAMTC) is a thioderivative of 4-methyl coumarin ([@b5-ol-0-0-10146]). Coumarins belong to the flavonoid class of plant secondary metabolite, which have been demonstrated to exhibit diverse and beneficial biological activities, including antitumoral, anticoagulant and anti-inflammatory properties ([@b5-ol-0-0-10146]). Natural coumarins or synthetic analogs have attracted intense interest for their applicability as drugs ([@b6-ol-0-0-10146]). They have been determined to have a variety of therapeutic applications, including antitumor and anti-human immunodeficiency virus therapy ([@b7-ol-0-0-10146]), and antioxidant ([@b8-ol-0-0-10146]) and antibacterial ([@b9-ol-0-0-10146]) applications. Lacy and O\'Kennedy ([@b10-ol-0-0-10146]) demonstrated that genistein and esculetin could exert the most potent inhibitory effect on cell growth of two cell lines, A549, a lung carcinoma cell line, and MCF-7, a breast carcinoma cell line. Previously, the coumarin derivative DAMTC was indicated to inhibit cellular proliferation and induce apoptosis on human non-small cell lung cancer A549 cells ([@b11-ol-0-0-10146]). Furthermore, the observations of Goel *et al* ([@b12-ol-0-0-10146]) reported that upregulation of the nuclear factor-κB, p53 and Akt pathways, and downregulation of the mitogen activated protein kinase (MAPK) and Cox-2 pathways were involved in the molecular mechanism of apoptosis induction by DAMTC in A549 cells. However, the mechanisms of the anti-proliferative effects of DAMTC in lung adenocarcinoma are incompletely defined, and further insights into the mechanisms are required.

Previously, Goel *et al* ([@b1-ol-0-0-10146]) used the integrated proteomics and transcriptomics approach, and identified that DAMTC could regulate cell motility and cytoskeletal reorganization in lung adenocarcinoma. In the present study, differentially-expressed genes (DEGs) were identified in DAMTC-treated lung adenocarcinoma, compared with DAMTC-untreated controls, using the same gene expression profile. Comprehensive bioinformatics were used to analyze the significant pathways and functions, and to construct the protein-protein interaction (PPI) network, to determine the critical DEGs. Furthermore, the putative interactions between signaling pathways were analyzed. The present study aimed to investigate the potential molecular mechanism underlying DAMTC-induced apoptosis and inhibition of cell motility in lung adenocarcinoma.

Materials and methods
=====================

### Microarray data and data preprocessing

The gene expression profile of GSE29698, deposited by Goel *et al* ([@b1-ol-0-0-10146]), was downloaded from the Gene Expression Omnibus database in National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/geo/>) based on the platform of GPL6884 Illumina HumanWG-6 v3.0 expression beadchip. A total of 6 specimens were applied, including 3 specimens of DAMTC-treated lung adenocarcinoma cells (A549) and another 3 specimens of DAMTC-untreated A549 cell lines as controls.

The gene expression profile data were preprocessed using the limma ([@b13-ol-0-0-10146]) package in Bioconductor. Following background correction, quantile normalization and probe summarization, the gene expression matrix of specimens was received.

### DEGs screening

Unpaired Student\'s t-test ([@b13-ol-0-0-10146]) in limma package was used to identify the DEGs in the DAMTC-treated A549 cell group, compared with the control group. False discovery rate (FDR) ([@b14-ol-0-0-10146]) was performed for multiple testing correction using the Benjamini and Hochberg method ([@b15-ol-0-0-10146]). The threshold for the DEGs was set as FDR \<0.01 and \|log~2~ FC (fold change) \|≥2.

### Functional and pathway enrichment analysis of DEGs

Gene Ontology (GO) ([@b16-ol-0-0-10146]) categories, including biological process (BP), molecular function (MF) and cellular component (CC), of the selected DEGs were enriched from GO databases using Database for Annotation Visualization and Integrated Discovery (DAVID) ([@b17-ol-0-0-10146]). Additionally, the pathways of selected DEGs were enriched using DAVID from Kyoto Encyclopedia of Genes and Genomes (KEGG) ([@b18-ol-0-0-10146]) analysis. P\<0.05, as determined by the hypergeometric test ([@b19-ol-0-0-10146]), was selected as the threshold.

### Functional annotation of DEGs

Identification of tumor-associated genes (TAGs) and understanding their functions can be critical for investigating the roles of genes involved in tumorigenesis. The tumor suppressor gene (TSGene) database (<http://bioinfo.mc.vanderbilt.edu/TSGene/>) is a comprehensive literature-based database that provides detailed annotations for each TSG. The TAG database (<http://www.binfo.ncku.edu.tw/TAG/>) is designed to utilize information from well-characterized oncogenes and tumor suppressor genes to accelerate cancer research. According to the data information regarding transcription factors (TFs) from the TRANSFAC database ([@b20-ol-0-0-10146]), functional enrichment of the DEGs for transcription regulation was assessed. Additionally, the selected DEGs were mapped into the TSGene and TAG database to extract the genes that had transcriptional functions or functioned as TAGs.

### PPI network construction

The PPI network is represented by an undirected graph with nodes indicating the genes and edges indicating the mapped interactions of the proteins encoded by the genes ([@b21-ol-0-0-10146]). The PPI network of the selected genes was constructed by using data from the Retrieval of Interacting Genes (STRING) database, which is a comprehensive database containing functional associations between proteins that are experimentally derived, as well as associations predicted by comparative genomics and text mining ([@b22-ol-0-0-10146]). The interaction pairs with the PPI combined score \>0.4 were selected in this network, which corresponded to a medium-confidence network ([@b23-ol-0-0-10146]).

### Pathway crosstalk analysis

If more significant protein interactions are detected between two pathways, these two pathways are probable to influence or interact with each other (cross-talk). Understanding the crosstalk between pathways is momentous for understanding the function of cells and more complex systems ([@b24-ol-0-0-10146]). In the present study, the KEGG pathway data and protein interaction data based on the PPI network were combined to investigate pathway crosstalk in the DAMTC-treated A549 cells. The detail is included in the studies by Li *et al* ([@b24-ol-0-0-10146]) and Liu *et al* ([@b25-ol-0-0-10146]).

Results
=======

### Identification of DEGs

For the dataset GSE29698, a total of 889 DEGs were identified in DAMTC-treated A549 cell groups, compared with DAMTC-untreated controls, including 500 upregulated genes and 389 downregulated genes. The heat-map of the DEGs is depicted in [Fig. 1](#f1-ol-0-0-10146){ref-type="fig"}. The results demonstrated that the DEGs expression pattern could significantly distinguish the DAMTC-treated A549 cell samples from controls.

### GO and pathway enrichment analysis of the DEGs

Functional and pathway enrichment analysis indicated that upregulated and downregulated DEGs in DAMTC-treated A549 cell groups were significantly enriched in different GO terms and KEGG pathways ([Tables I](#tI-ol-0-0-10146){ref-type="table"} and [II](#tII-ol-0-0-10146){ref-type="table"}). GO analysis demonstrated enrichment in upregulated DEGs involved in BP, including transcription, DNA-dependent and regulation of cellular metabolic process. Significant CC ontology terms of upregulated DEGs were associated with intracellular part. The majority of significant MF ontology terms of upregulated DEGs were associated with binding function and enzyme activity, including DNA binding and phosphatase activity. Furthermore, significant BP ontology terms of downregulated DEGs were associated with tissue morphogenesis, and morphogenesis of an epithelium. CC ontology terms of downregulated DEGs were also associated with intracellular part. Significant MF ontology terms of downregulated DEGs were associated with organic cyclic compound binding, and RNA polymerase II transcription corepressor activity ([Table I](#tI-ol-0-0-10146){ref-type="table"}).

Additionally, upregulated DEGs were enriched in different pathways, including the p53 signaling pathway, and fructose and mannose metabolism pathway. Downregulated DEGs were also identified to be involved in different pathways, including ubiquitin mediated proteolysis, and metabolic pathways ([Table II](#tII-ol-0-0-10146){ref-type="table"}).

### Function annotation of DEGs

The expression change of TFs, TSGs and other TAGs in DAMTC-treated A549 cell groups were observed ([Table III](#tIII-ol-0-0-10146){ref-type="table"}). The upregulated functional genes included 34 TFs and 26 TSGs. Subsequently, *MAX* was identified to be a TF, while tumor protein p53 inducible nuclear protein 1 and bone morphogenetic protein 2 were identified to be TSGs. Additionally, histone deacetylase 3 (*HDAC3*) was identified as both a TF and a TSG. Additionally, the downregulated functional genes included 27 TFs and 18 TSGs. Among them, sex determining region Y-box 4 and signal transducer and activator of transcription 1 (*STAT1*) were identified to be TFs.

### PPI network and the pathway crosstalk analysis

Based on the STRING database, the PPI network was constructed ([Fig. 2](#f2-ol-0-0-10146){ref-type="fig"}). The results demonstrated that a total of 9 genes had a node degree \>16, including interleukin 6 (*IL6*; degree, 37), MDM2 oncogene, E3 ubiquitin protein ligase (*MDM2*; degree, 27), *STAT1* (degree, 23), ataxia telangiectasia mutated (degree, 20), *HDAC3* (degree, 19), cell division cycle 42 (*CDC42*; degree, 18), cytochrome c, somatic (degree, 17), bone morphogenetic protein 4 (degree, 17) and *MAX* (degree, 17).

The result of pathway crosstalk analysis is depicted in [Fig. 3](#f3-ol-0-0-10146){ref-type="fig"}. The majority of the significant pathways were determined to have crosstalk with small cell lung cancer and non-small cell lung cancer. The apoptosis, tight junction and endocytosis pathways were determined to be cross-talking with small cell lung cancer and non-small cell lung cancer. Additionally, the bacterial invasion of epithelial cells, adherens junction, shigellosis and mechanistic target of rapamycin kinase signaling pathways had cross-talk with non-small cell lung cancer. In addition, small cell lung cancer and non-small cell lung cancer were also determined to have cross-talk.

Discussion
==========

The worldwide incidence rate of lung cancer is high ([@b26-ol-0-0-10146]). It is important to develop novel, more effective treatment modalities for dealing with this disease. DAMTC is a potential inducer of apoptosis and an inhibitor of cell growth ([@b1-ol-0-0-10146]). Thus, identifying the molecular mechanism underlying the effects of DAMTC is imperative. In the present study, microarray analysis demonstrated that 500 upregulated DEGs and 389 downregulated DEGs were identified in DAMTC-treated A549 cells, compared with DAMTC-untreated controls. Among the DEGs, *IL6*, which was downregulated, was a hub protein with the highest degree in the PPI network. The upregulated DEGs *MDM2, CDC42* and *MAX*, which were also hub genes, had different functions and were involved in different pathways, including the p53 signaling and endocytosis pathways. Additionally, the apoptosis, tight junction, and endocytosis pathways were determined to cross-talk with small cell lung cancer and non-small cell lung cancer.

*IL6* encodes a multifunctional cytokine, which can function in inflammation and the maturation of B cells ([@b27-ol-0-0-10146]). Hodge *et al* ([@b28-ol-0-0-10146]) demonstrated that the release of various survival factors, including IL6, serve to block apoptosis in cancer cells during the inflammatory process, keeping them alive in toxic environments. Additionally, studies have demonstrated that drugs designed to restore apoptosis exhibit potential to effectively treat numerous cancer types, including inhibitors of apoptosis, protein inhibitors and MDM2 antagonists ([@b29-ol-0-0-10146],[@b30-ol-0-0-10146]). Furthermore, in keeping with the previous study, our study identified that IL6 was downregulated in DAMTC-treated A549 groups and was involved in the pathways in cancer ([Table I](#tI-ol-0-0-10146){ref-type="table"}). Thus, it was indicated that DAMTC may induce cancer cell apoptosis through targeting *IL6* in lung adenocarcinoma.

Additionally, the other upregulated DEG *MAX* was enriched in the pathways in cancer and identified to be a TAG in the present study. MAX is a member of the basic helix-loop-helix leucine zipper family of TFs and could interact with other family members, including v-myc avian myelocytomatosis viral oncogene homolog (MYC), MAX interactor 1, dimerization protein and mothers against decapentaplegic (MAD), to form homodimers or heterodimers ([@b31-ol-0-0-10146]). The study by Grandori *et al* ([@b32-ol-0-0-10146]) demonstrated that the MYC/MAX/MAD network was comprised of a group of TFs controlling cell cycle differentiation, progression and death. Additionally, Zhu *et al* ([@b33-ol-0-0-10146]) reported that levels of MAD1 rapidly decrease upon mitogen stimulation, and this degradation could be regulated by the MAPK pathway. Furthermore, Goel *et al* ([@b34-ol-0-0-10146]) reported that DAMTC could induce apoptosis through the mitochondrial pathway by modulating the MAPK pathway. Thus, it was indicated that DAMTC may induce cell apoptosis by upregulating the expression of *MAX* and modulating the MAPK pathway in lung adenocarcinoma.

Furthermore, pathway crosstalk analysis in the present study demonstrated that apoptosis, tight junction and endocytosis had cross-talks with non-small and small lung cancer. Additionally, the present study also revealed that *MDM2* and *CDC42*, which were another two hub genes in the PPI network, were identified to be involved in different pathways, including the p53 signaling and endocytosis pathways. *MDM2* encodes a nuclear-localized E3 ubiquitin ligase that mediates ubiquitination of p53 ([@b35-ol-0-0-10146]). Oren ([@b36-ol-0-0-10146]) demonstrated that proteins encoded by one or more p53 target genes could serve an essential role in causing p53-mediated apoptosis. This was consistent with the observations by Goel *et al* ([@b12-ol-0-0-10146]), demonstrating that DAMTC could induce apoptosis by modulating the p53 pathway in A549 cells. For the other DEG, CDC42 is a small GTPase of the Rho-subfamily, which can regulate signaling pathways that control numerous cellular functions, including cell endocytosis, migration and cell cycle progression ([@b37-ol-0-0-10146]). Georgiou *et al* ([@b38-ol-0-0-10146]) reported that *CDC42* could act together with par-6 family cell polarity regulator and protein kinase C in the regulation of Arp2/3-mediated endocytosis to control local adherens junction stability, modulating actin filament dynamics ([@b38-ol-0-0-10146]). Additionally, Mosesson *et al* ([@b39-ol-0-0-10146]) revealed that aberrant endocytosis of transmembrane proteins could contribute to malignant transformation. Furthermore, Goel *et al* ([@b34-ol-0-0-10146]) demonstrated that DAMTC could inhibit cell motility in A549 cells. Collectively, it was confirmed that DAMTC could induce cancer cell apoptosis by modulating the p53 pathway. In addition, it was indicated that DAMTC may inhibit cell motility through targeting *CDC42* and affecting the endocytosis pathway in lung adenocarcinoma.

In conclusion, the present study determined a network of genes, including *IL6, MDM2, CDC42* and *MAX*, targeted by DAMTC that participated in different pathways were involved in the mechanism of DAMTC-treated lung adenocarcinoma. DAMTC may induce cell apoptosis by targeting *IL6* and *MAX*, which was involved in the MAPK pathway in lung adenocarcinoma. Additionally, DAMTC may inhibit cell motility through targeting *CDC42* and affecting the endocytosis pathway in lung adenocarcinoma. These activities may contribute to the anti-carcinogenic action of DAMTC. Due to the relatively small number of samples in the present study, further studies using a larger sample size to validate and determine the role of the potential molecular mechanism identified are required. Ongoing studies may emphasize the potential of DAMTC as an anticancer therapeutic.
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###### 

The enriched GO terms of differentially-expressed genes in 7, 8-diacetoxy-4-methylcoumarin-treated lung cancer groups.

  Expression changes   Category   GO-ID        Name                                                                                                                            Count   P-value
  -------------------- ---------- ------------ ------------------------------------------------------------------------------------------------------------------------------- ------- --------------
  Upregulated          BP         GO:0006351   Transcription, DNA-dependent                                                                                                    153     3.30×10^−11^
                                  GO:0031323   Regulation of cellular metabolic process                                                                                        194     7.80×10^−11^
                                  GO:0060255   Regulation of macromolecule metabolic process                                                                                   187     8.24×10^−11^
                                  GO:0051252   Regulation of RNA metabolic process                                                                                             143     1.56×10^−10^
                                  GO:0019222   Regulation of metabolic process                                                                                                 207     2.08×10^−10^
                       CC         GO:0005622   Intracellular                                                                                                                   387     2.45×10^−10^
                                  GO:0044424   Intracellular part                                                                                                              382     1.08×10^−9^
                                  GO:0005634   Nucleus                                                                                                                         219     2.68×10^−9^
                                  GO:0043227   Membrane-bounded organelle                                                                                                      320     5.19×10^−9^
                                  GO:0043231   Intracellular membrane-bounded organelle                                                                                        319     5.71×10^−9^
                       MF         GO:0003677   DNA binding                                                                                                                     98      3.25×10^−5^
                                  GO:0016791   Phosphatase activity                                                                                                            18      4.00×10^−4^
                                  GO:0000988   Protein binding transcription factor activity                                                                                   28      8.00×10^−4^
                                  GO:0005515   Protein binding                                                                                                                 244     11.00×10^−3^
                                  GO:0005488   Binding                                                                                                                         362     13.00×10^−3^
  Downregulated        BP         GO:0048729   Tissue morphogenesis                                                                                                            28      2.61×10^−6^
                                  GO:0002009   Morphogenesis of an epithelium                                                                                                  24      3.72×10^−6^
                                  GO:0044237   Cellular metabolic process                                                                                                      221     7.50×10^−5^
                                  GO:0044238   Primary metabolic process                                                                                                       224     8.50×10^−5^
                                  GO:0048736   Appendage development                                                                                                           12      8.77×10^−5^
                       CC         GO:0044424   Intracellular part                                                                                                              291     3.52×10^−8^
                                  GO:0043231   Intracellular membrane-bounded organelle                                                                                        243     1.83×10^−7^
                                  GO:0005622   Intracellular                                                                                                                   291     2.11×10^−7^
                                  GO:0043227   Membrane-bounded organelle                                                                                                      243     2.69×10^−7^
                                  GO:0043229   Intracellular organelle                                                                                                         257     2.01×10^−6^
                       MF         GO:0097159   Organic cyclic compound binding                                                                                                 154     2.31×10^−6^
                                  GO:1901363   Heterocyclic compound binding                                                                                                   152     2.77×10^−6^
                                  GO:0001191   RNA polymerase II transcription factor binding transcription factor activity involved in negative regulation of transcription   6       2.35×10^−5^
                                  GO:0001106   RNA polymerase II transcription corepressor activity                                                                            5       3.99×10^−5^
                                  GO:0003714   Transcription corepressor activity                                                                                              14      8.22×10^−5^

GO, gene ontology; CC, cellular component; BP, biological process; MF, molecular function.

###### 

The enriched pathways of differentially-expressed genes in 7, 8-diacetoxy-4-methylcoumarin-treated lung cancer groups.

  Expression changes   KEGG-ID   Name                                                  n    P-value   Genes
  -------------------- --------- ----------------------------------------------------- ---- --------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Upregulated          04115     p53 signaling pathway                                 9    0.0001    APAF1, CCNG2, CYCS, GADD45A, MDM2, PPM1D, RPRM, SESN1 and SESN3
                       00051     Fructose and mannose metabolism                       5    0.0032    ALDOC, C12orf5, HK2, MTMR1 and PFKFB4
                       05219     Bladder cancer                                        5    0.0062    FGFR3, MAP2K1, MDM2, PGF and RASSF1
                       04722     Neurotrophin signaling pathway                        9    0.0095    CDC42, GAB1, MAP2K1, MAP3K3, MAPK7, NFKBIE, NTF3, PDK1 and ZNF274
                       05200     Pathways in cancer                                    17   0.0103    BMP2, CCNA1, CDC42, CYCS, EGLN1, FGF18, FGFR3, FZD1, FZD4, FZD7, MAP2K1, MAX, MDM2, PGF, PIAS3, RASSF1 and RASSF5
                       04130     SNARE interactions in vesicular transport             4    0.0180    BNIP1, STX11, STX7 and VAMP1
                       04144     Endocytosis                                           11   0.0265    CDC42, CXCR4, DNM2, FGFR3, GIT2, HLA-E, MDM2, RAB11FIP1, SH3GL2, SH3GL3 and VPS37B
                       05211     Renal cell carcinoma                                  5    0.0472    CDC42, EGLN1, GAB1, MAP2K1 and PGF
  Downregulated        05217     Basal cell carcinoma                                  6    0.0008    BMP4, FZD2, GLI2, STK36, TCF7L2 and WNT7B
                       00130     Ubiquinone and other terpenoid-quinone biosynthesis   2    0.0079    COQ5 and COQ7
                       01100     Metabolic pathways                                    33   0.0130    ACSS1, AK2, ATP6V1E2, B3GALT6, BAAT, BCAT1, COQ5, COQ7, CYP2R1, DPAGT1, GGPS1, GPT2, HKDC1, HLCS, OXSM, PAFAH2, PCK2, PFAS, PIGM, PIGV, PIGW, PIK3C2B, PLD1, PMM2, POLG2, POLR1B, POLR3H, PSPH, SEPHS2, SLC33A1, ST3GAL5, ST6GAL1 and SYNJ2
                       00563     Glycosylphosphatidyli-nositol-anchor biosynthesis     3    0.0132    PIGM, PIGV and PIGW
                       04120     Ubiquitin mediated proteolysis                        7    0.0185    ANAPC13, BIRC6, FBXO4, ITCH, KLHL9, UBE2J1 and UBE2Q1
                       04340     Hedgehog signaling pathway                            4    0.0255    BMP4, GLI2, STK36 and WNT7B
                       05200     Pathways in cancer                                    12   0.0300    BMP4, DAPK1, FZD2, GLI2, IL6, PLD1, RARB, STAT1, STK36, TCF7L2, TRAF5 and WNT7B

n, number of genes enriched in the corresponding pathway; KEGG, Kyoto Encyclopedia of Genes and Genomes.

###### 

Functional annotation of differentially-expressed genes in 7, 8-diacetoxy-4-methylcoumarin-treated lung cancer groups.

  Expression changes   TF                                                                                                                                                                                                                               TSG                                                                                                                                                                                                   Other TAG
  -------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------
  Upregulated          ATF2, BCL6, CDK7, ERCC6, EZH2, FOXD1, GATA2, GATA4, GMEB1, GTF2B, HAND1, HDAC3, HEY2, HOXD10, HOXD11, ING1, IRF7, IRF8, IRX5, ISL1, MAFB, MAFF, MAX, MEF2A, NFIL3, PAX9, PLAGL1, RFX2, RORA, SOX8, TMF1, VDR, ZNF10 and ZNF133   APAF1, ARID3B, BCL10, BIK, BMP2, BRMS1, CAMTA1, CDKN1C, CDKN2D, DDX3X, EGLN1, FBXW7, HDAC3, ING1, IRF8, LATS2, NDRG1, PHF6, PLAGL1, PLEKHO1, PPP1R3C, RASSF1, RASSF5, SLC9A3R1, TMEFF2 and TP53INP1   CHRM3, FZD7, LGALS8, MAFB, MAP1A, MAX, PIAS3 and RGS2
  Downregulated        AKNA, CEBPG, FOXL2, FOXQ1, GATA3, GLI2, GTF2E1, HOXB5, HOXB8, HOXC8, MEIS1, MEIS2, MSC, NFIA, NFIB,NPAS2, NR2E3, NR2F2, NR5A2, PBX1, PRDM1, SMAD6, SOX4, STAT1, TBX18, TCF7L2 and XBP1                                           ABLIM3, ARID1A, ASXL1, CDH4, COL4A3, DAB2, DAPK1,DFNA5, DKK1, KCNRG, KRIT1, MN1, MTUS1, NRCAM, PLK2, PRDM1, RARB and TCF7L2                                                                           ATM, PMS1, RHOB, SSPN and TFAP2A

TF, transcription factor; TSG, tumor suppression genes; TAG, tumor-associated gene.
